Stevanato Group Spa Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.4B+21.8% YoYTTM through 31 Dec 2025
Net Income $164.1M+34.6% YoYTTM through 31 Dec 2025
Free Cash Flow $22.3MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 29.0% |
| EBITDA Margin | 19.9% |
| Operating Margin | 16.8% |
| Net Margin | 11.8% |
Returns
9.4%ROE
5.5%ROA
7.9%ROIC
Balance Sheet Health
Debt / Equity0.32x
Current Ratio1.76x
Net Debt$337.7M
Cash & Equivalents$130.6M
Quality Metrics
Piotroski F-Score4 / 9
FCF Margin1.6%
Rule of 408.8
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.2B
Diluted EPSFY2025: $0.51
Dividend
$0.06Per share, FY20260.29%Yield
Capital Allocation
Capex Intensity18.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biopharmaceutical and Diagnostic Solutions (BDS) | View detailsThe segment continues to see strong demand driven by High-Value Solutions (HVS) such as Nexa syringes and GLP-1 related volumes, which represented approximately 19% to 20% of total Company revenue in fiscal year 2025. | ||
| Engineering | View detailsThe segment experienced weakness in fiscal year 2025 due to lower sales from glass converting and assembly lines, and is undergoing a business optimization plan to focus on higher-value visual inspection systems. |
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.